Alpine Immune Sciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALPN Nasdaq 8731 https://www.alpineimmunesciences.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alpine Immune Sciences Inc

Revolution Medicines, Inc. (RVMD) Surges 5.6%: Is This an Indication of Further Gains? - Jun 24th, 2022 1:42 pm
Great news for Alpine Immune Sciences, Inc. (NASDAQ:ALPN): Insiders acquired stock in large numbers last year - Jun 10th, 2022 11:03 am
Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer - Jun 7th, 2022 12:05 pm
Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022 - Jun 1st, 2022 12:05 pm
Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings - May 26th, 2022 9:30 pm
FDA Lifts Partial Hold On Alpine Immune's Davoceticept Combo Trial In Advanced Cancer - May 24th, 2022 12:54 pm
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab - May 24th, 2022 12:05 pm
Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Tops Revenue Estimates - May 12th, 2022 9:55 pm
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results - May 12th, 2022 8:05 pm
Alpine Immune Sciences (NASDAQ:ALPN) pulls back 14% this week, but still delivers shareholders favorable 14% CAGR over 3 years - May 11th, 2022 10:27 am
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates - May 9th, 2022 9:45 pm
Endo International (ENDP) Surpasses Q1 Earnings and Revenue Estimates - May 5th, 2022 11:15 pm
Alpine Immune Sciences Announces Participation in May Investor Conferences - May 3rd, 2022 12:05 pm
AACR 2022: Davoceticept (ALPN-202) Monotherapy Reduces Tumors, Supports Multiple Expansion Cohorts - Apr 12th, 2022 9:05 pm
Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event - Apr 5th, 2022 8:05 pm
Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications - Apr 4th, 2022 12:05 pm
Alpine Immune Sciences to Host Virtual Investor Event at 2022 AACR Annual Meeting - Mar 30th, 2022 12:05 pm
Alpine Immune Sciences, Inc. (ALPN) Soars 6%: Is Further Upside Left in the Stock? - Mar 24th, 2022 1:30 pm
Oppenheimer Predicts Over 90% Rally for These 2 Stocks - Mar 23rd, 2022 12:48 am
Here's Why Alpine Immune Sciences (NASDAQ:ALPN) Can Manage Its Debt Despite Losing Money - Mar 21st, 2022 10:40 pm